Blar i forfatter "Besada, Emilio"
-
CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in Granulomatosis with polyangiitis patients
Besada, Emilio; Nossent, Johannes C. (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-09-20)<b>Introduction</b> <br> Rituximab (RTX) is a B cell-depleting agent approved for the treatment of granulomatosis with polyangiitis (GPA). RTX reduces antibody producing precursor plasma cells and inhibits B and T cells interaction. Infections related to T cell immunodeficiency are not infrequent during RTX treatment. Our study investigated CD4 cell count and CD4/CD8 ratio in GPA patients during the ... -
CHRONIC NASAL CARRIAGE OF STAPHYLOCOCCUS AUREUS DOES NOT INCREASE THE RISK OF RELAPSE AND SEVERE INFECTIONS IN GRANULOMATOSIS WITH POLYANGIITIS PATIENTS WHEN RECEIVING RITUXIMAB MAINTENANCE TREATMENT
Besada, Emilio; Koldingsnes, Wenche; Nossent, Johannes C (Conference object; Konferansebidrag, 2014-06-10) -
Chronic nasal carriage of Staphylococcus aureus in granulomatosis with polyangiitis patients receiving rituximab maintenance: friend or foe?
Besada, Emilio; Koldingsnes, Wenche; Nossent, Johannes C (Journal article; Tidsskriftartikkel, 2014) -
Comment on: Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice
Besada, Emilio (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-01-19) -
CRP as a marker for myocardial infarction and for damage accrual in systemic lupus erythematosus patients: results from a single-centre longitudinal study
Besada, Emilio; Nossent, Johannes C (Journal article; Tidsskriftartikkel; Peer reviewed, 2012)CRP is a marker of inflammation and is also a known cardiovascular risk factor. Patients with systemic lupus erythematosus (SLE) have moderately elevated CRP levels and develop organ damage , that includes an increased rate of cardiovascular events. -
CRP as a marker for myocardial infarction and for damage accrual in systemic lupus erythematosus: results from a single-center longitudinal study.
Besada, Emilio; Nossent, Johannes C (Conference object; Konferansebidrag, 2012) -
Cyclophosphamide effect on immunoglobulins levels in AAV patients treated with long-term pre-emptive rituximab maintenance.
Besada, Emilio; Koldingsnes, Wenche; Nossent, Johannes C (Conference object; Konferansebidrag, 2013) -
Diagnostic value of antibodies against mutated citrullinated vimentin for rheumatoid arthritis
Besada, Emilio; Nikolaisen, Cathrin; Nossent, Johannes C (Journal article; Tidsskriftartikkel; Peer reviewed, 2011)OBJECTIVES: To compare the diagnostic efficiency of anti-MCV, anti-CCP2 and RF detection for patients with RA. METHODS: Cross-sectional study of patients with established rheumatic disease: rheumatoid arthritis (RA; n=75), psoriatic arthritis (PsA; n=25), 27 patients with ankylosing spondylitis (AS; n=27) and connective tissue disease (CTD; n=17). Anti-CCP2, anti-MCV and RF were detected by ... -
Does concomitant methotrexate during rituximab treatment in granulomatosis with polyangiitis (Wegener's) increase the risk of severe infection? Comment on the article by Azar et al
Besada, Emilio; Diamantopoulos, Andreas P (Journal article; Tidsskriftartikkel, 2015-06-26) -
Efficacy of chronic pre-emptive rituximab treatment in ANCA-associated vasculitis
Besada, Emilio; Nossent, Johannes C (Conference object; Konferansebidrag, 2012) -
Efficacy of chronic pre-emptive rituximab treatment in ANCA-associated vasculitis
Besada, Emilio; Nossent, Johannes C (Journal article; Tidsskriftartikkel; Peer reviewed, 2012) -
Er det forskjell på subkutan og intravenøs tocilizumab ved behandling av revmatoid artritt?
Besada, Emilio (Journal article; Tidsskriftartikkel, 2015) -
GP-confirmed complete Achilles tendon rupture using pocket-sized ultrasound: a case report
Davis, Simon; Lott, Alexander; Besada, Emilio (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-25)The incidence of complete Achilles tendon rupture is 18 per 100 000 patient-years and is usually diagnosed clinically by GPs. The extent of clinical misdiagnosis is unknown in Norway, but may be high. This is important as delayed treatment has unfavourable consequences. We report how a GP, with no clinical ultrasound experience, recorded images with a pocket-sized ultrasound device (PSUD) under ... -
Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in Granulomatosis with Polyangiitis: results from a single centre.
Besada, Emilio; Koldingsnes, Wenche; Nossent, Johannes C (Conference object; Konferansebidrag, 2013)Objective: Rituximab (RTX) is an anti-CD20 antibody used successfully in Granulomatosis with Polyangiitis (GPA) for induction and maintenance of remission. Our study aims to evaluate the long term efficacy and safety of chronic pre-emptive RTX therapy in GPA. -
Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in Granulomatosis with Polyangiitis: results from a single centre.
Besada, Emilio; Koldingsnes, Wenche; Nossent, Johannes C (Journal article; Tidsskriftartikkel; Peer reviewed, 2013)Rituximab (RTX) is an anti-CD20 antibody used successfully in granulomatosis with polyangiitis (GPA) for induction and maintenance of remission. Our study aims to evaluate the long-term efficacy and safety of chronic pre-emptive RTX therapy in GPA. Retrospective study of 35 GPA patients treated with RTX between April 2004 and September 2011 for active disease and maintenance. RTX was initiated as ... -
Low CD4/CD8 ratio is associated with lower immunoglobulin levels in granulomatosis with polyangiitis patients receiving rituximab
Besada, Emilio; Nossent, Johannes C (Journal article; Tidsskriftartikkel, 2014-09-03) -
Low CD4/CD8 ratio is associated with lower immunoglobulin levels in granulomatosis with polyangiitis patients receiving Rituximab
Besada, Emilio; Nossent, Johannes C (Journal article; Tidsskriftartikkel, 2014) -
Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab
Besada, Emilio (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-01-06)Background: Randomized controlled trials and retrospective studies in ANCA-associated vasculitis (AAV) concurred that rituximab (RTX) is effective to induce and maintain remission. Infections and hypogammaglobulinemia during RTX were usually infrequent and uncomplicated. But in the Tromsø study cohort, 45 % of patients with granulomatosis with polyangiitis (GPA) developed hypogammaglobulinemia ... -
Pneumocystis jiroveci pneumonia prophylaxis is a challenge in granulomatosis with polyangiitis patients treated with rituximab
Besada, Emilio (Journal article; Tidsskriftartikkel, 2013) -
Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review.
Besada, Emilio (Journal article; Tidsskriftartikkel; Peer reviewed, 2014)Treatment of rheumatoid arthritis (RA) was revolutionized during the last decade with the development of new biologic disease-modifying anti-rheumatic drugs (DMARDs) enabling the targeting of immune cells and cytokines other than tumor necrosis factor (TNF). Subcutaneous formulations of the newer biologic DMARDs facilitate not only patients’ emancipation from the hospital, but reduce both societal ...